Alpha Tau Medical Ltd. (NASDAQ:DRTS) Sees Large Increase in Short Interest

Alpha Tau Medical Ltd. (NASDAQ:DRTS) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 122,000 shares, a growth of 60.7% from the February 28th total of 75,900 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 89,000 shares, the short-interest ratio is presently 1.4 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in shares of Alpha Tau Medical by 188.7% during the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after acquiring an additional 26,800 shares during the period. Northern Trust Corp increased its stake in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after acquiring an additional 25,770 shares during the last quarter. Finally, Levin Capital Strategies L.P. increased its position in shares of Alpha Tau Medical by 2.3% in the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after buying an additional 7,189 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors.

Alpha Tau Medical Trading Down 3.8 %

Shares of Alpha Tau Medical stock traded down $0.10 during trading on Friday, reaching $2.56. The company’s stock had a trading volume of 25,356 shares, compared to its average volume of 48,716. Alpha Tau Medical has a one year low of $1.75 and a one year high of $4.39. The stock has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $2.81. The stock has a market capitalization of $180.18 million, a P/E ratio of -5.95 and a beta of 0.87.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). As a group, sell-side analysts anticipate that Alpha Tau Medical will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Alpha Tau Medical in a research report on Monday, March 17th.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.